Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-1 Refractory Disease ... | May 10, 2022
Source: marketscreener.com